Navigation Links
Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
Date:10/18/2010

the October 2009 Complete Response Letter."

Thomas Roth, Ph.D., Director, Sleep Disorders and Research Center, Henry Ford Hospital, said, "This study represents a robust approach to characterizing the effect of a sleep aid candidate on next morning driving ability, and serves as a model for the future testing of medication driving safety.  Findings from the highway driving study provide good evidence to support the view that Intermezzo® shows no significantly increased risk of driving impairment when taken with at least four hours remaining in bed.  Intermezzo® has the potential to be an important treatment for those insomnia patients whose only current option to treat a middle of the night awakening is to take a 7 to 8 hour sleep aid at bedtime in anticipation of an awakening that may not occur."

Transcept plans to resubmit the Intermezzo® NDA in the first quarter of 2011, and anticipates a six-month review by the FDA.  In the revised NDA, Transcept plans to address FDA concerns raised in an October 2009 Complete Response Letter by submitting the results of the highway driving study, a revised unit dose package, new patient tools to reinforce the importance of proper dosing, and new epidemiology findings that quantify the current off-label use of 7 to 8 hour hypnotics in the middle of the night.

Transcept estimates that cash, cash equivalents and marketable securities at September 30, 2010 were approximately $74 million, and believes these resources will be sufficient to allow for the resubmission of the Intermezzo® NDA and to complete the planned placebo-controlled study of ultra low dose ondansetron as an adjunctive treatment of obsessive compulsive disorder.

About the Intermezzo® Development Program Transcept completed pre-clinical and clinical studies of Intermezzo®, including two Phase 3 clinical trials, in 2008.  The
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at BIO Investor Forum
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
7. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
8. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
10. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
11. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... July 25, 2014  Solanbridge Group Inc (OTC: SLNX) ... majority interest in Buzznbrewz.com and the Letter of Intent ... a fully executed Purchase Agreement. Charles ... are proud to have Mr. David Pecoraro ... experience in the private sector and developed a tremendous ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Results of Largest Randomized, Placebo-controlled Trial,Ever Conducted ... of,Clinical Oncology, CHICAGO, June 04, 2007 /PRNewswire/ ... clinical trial ever,conducted in patients with cutaneous ... than twice as effective as placebo in ...
... in Patients With Follicular Lymphoma Reported,Today at ... /PRNewswire/ -- GlaxoSmithKline plc,announced today long-term efficacy ... a,single one-week course of frontline treatment with ... Tositumomab) in,76 patients with newly diagnosed advanced ...
Cached Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... July 28, 2014 Maternal and Family ... Tucker Award, which will be presented at the agency’s ... October 29th at the Westmoreland Club in Wilkes-Barre. , ... Commissioner and long-time employee of MFHS. She dedicated ... political activist, health advocate, and champion for women, children ...
(Date:7/28/2014)... that following a healthy lifestyle may lower childhood cancer ... online in CANCER , a peer-reviewed journal of ... with cancer and adults who had cancer when they ... may influence their long-term health. , Adults who ... increased risk for the metabolic syndrome, a group of ...
(Date:7/28/2014)... As health insurers design their strategies ... exchanges. “Private Exchange Strategies for Insurers: What’s Working? ... Information Services, will provide answers to the big-dollar questions ... future. , Barbara Gniewek, Jonathan Har-Even and Martin Hill ... the private exchange sector — will provide expert presentations ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... Results from two,studies comparing colorectal cancer screening ... called virtual colonoscopy),have sparked interest in colorectal cancer ... consumers. The studies, one a large multi-center,trial sponsored ... other from the,University of Wisconsin published in the ...
... Health COO First Annual Honoree, SOMERSET, N.J., Oct. ... (Nasdaq: VTIV ) and President and CEO,of inVentiv ... Big,Brothers Big Sisters(R) (BBBS) of Hunterdon & Somerset Counties ... Moments, Big Magic -- A,Match That Lights an Eternal ...
... Liver, NEW YORK, Oct. 5 Urging every ... (ALF) today observed Liver,Awareness Month by releasing 12 tips ... Liver disease, a serious and largely unrecognized problem in ... among adults between the ages of,25 and 64, taking ...
... month a collaboration of European and Asian researchers launched ... harnessing the combined power of more than 40,000 computers ... drug discovery. , Called Enabling Grids for E-sciencE, the ... supercomputer that is being used during this challenge to ...
... Tenn., Oct. 5 Emdeon Business Services,announced ... Delta Dental payers for,insurance eligibility and benefits ... vendor partners and through the Emdeon suite ... Provider Services,(DPS), Emdeon,s interactive web portal. Emdeon ...
... Mich., Oct. 5 Volkswagen of America,Inc., in ... Volkswagen,dealers, proudly announces its 12th consecutive year of ... delighted to continue our sponsorship for our 12th ... "The LaSalle Bank,Chicago Marathon is a great opportunity ...
Cached Medicine News:Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 2Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 3Health News:Terrell Herring Honored by Big Brothers Big Sisters 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 3Health News:Grid computing offers new hope in race against bird flu 2Health News:Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers 2Health News:Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon 2
... PROXIMATE Access 55 Articulating Linear Staplers are ... or a thick-tissue green instrument (non-reloadable). Each ... 55mm staple line., ,Benefits include: , ... in narrow male pelvis. , Articulating head ...
... Staplers deliver two staggered rows of titanium staples ... be reloaded up to three times for a ... wire staples for thick tissue. The TLV model ... ,Benefits include: , Parallel jaw closure ensures that ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
Single Use Reloadable Stapler with Titanium Staples., ,The Auto Suture™ PREMIUM MULTIFIRE TA™ stapler has applications in abdominal, gynecological, pediatric and thoracic surgical proced...
Medicine Products: